2,232 Shares in Illumina, Inc. (NASDAQ:ILMN) Acquired by Claro Advisors LLC

Claro Advisors LLC bought a new stake in Illumina, Inc. (NASDAQ:ILMN) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 2,232 shares of the life sciences company’s stock, valued at approximately $291,000.

A number of other hedge funds and other institutional investors have also modified their holdings of ILMN. Industrial Alliance Investment Management Inc. acquired a new position in shares of Illumina during the 2nd quarter valued at about $34,000. Versant Capital Management Inc boosted its holdings in Illumina by 292.9% in the 2nd quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company’s stock valued at $34,000 after purchasing an additional 246 shares during the last quarter. Massmutual Trust Co. FSB ADV grew its stake in shares of Illumina by 65.1% in the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock valued at $56,000 after buying an additional 168 shares during the period. Focused Wealth Management Inc acquired a new stake in shares of Illumina during the 3rd quarter worth approximately $63,000. Finally, Hollencrest Capital Management purchased a new stake in shares of Illumina during the 3rd quarter valued at approximately $63,000. 89.42% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. UBS Group raised their target price on Illumina from $133.00 to $145.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Citigroup boosted their price objective on shares of Illumina from $155.00 to $190.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. Daiwa Capital Markets raised shares of Illumina from a “neutral” rating to a “buy” rating and increased their target price for the stock from $120.00 to $154.00 in a research note on Friday, August 16th. Daiwa America raised shares of Illumina to a “strong-buy” rating in a research note on Friday, August 16th. Finally, TD Cowen increased their price objective on shares of Illumina from $166.00 to $177.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, fourteen have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $164.00.

Illumina Trading Down 3.2 %

NASDAQ ILMN opened at $130.74 on Tuesday. Illumina, Inc. has a 52 week low of $93.39 and a 52 week high of $156.66. The firm has a 50 day moving average of $139.82 and a two-hundred day moving average of $124.35. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94. The stock has a market capitalization of $20.74 billion, a PE ratio of -13.13 and a beta of 1.13.

Illumina (NASDAQ:ILMN) last issued its earnings results on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The firm had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.08 billion. During the same quarter in the previous year, the firm posted $0.33 earnings per share. The company’s revenue was down 3.5% compared to the same quarter last year. As a group, research analysts expect that Illumina, Inc. will post 4.11 EPS for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.